ICON Public Limited Company (NASDAQ:ICLR) Q2 2023 Earnings Call Transcript
Operator: Hello, and welcome to the ICON plc Q2 2023 Results Conference Call. At this time, all participants are in a listen only mode.
Stay updated with breaking news from Mapi Research Trust. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Hello, and welcome to the ICON plc Q2 2023 Results Conference Call. At this time, all participants are in a listen only mode.
Latest features support greater patient centricity and speed in study start-up
Treatment with benralizumab induced histological remission, defined as an absence of tissue eosinophilia, among patients with eosinophilic gastritis, according to a study published in The Lancet Gastroenterology & Hepatology.But the persistence of signs, symptoms and biomarkers of the disease during treatment suggested a pathogenic mechanism independent of eosinophil levels in many patients,
SAN ANTONIO — A high proportion of patients with eosinophilic esophagitis also had simultaneous atopic or allergic comorbid conditions, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.Eosinophilic esophagitis (EoE) is a chronic, progressive type II inflammatory disease, Marc E. Rothenberg, MD, PhD, director of the Cincinnati Center for
/PRNewswire/ -- The global eCOA solution market size is estimated to grow by USD 1,285.69 million from 2022 to 2027, according to Technavio. The market is...